Moreover, NfL release is proportional to the extent of myelin damage in MS; hence, the serum or CSF concentration of NfL may be associated with disease severity, treatment efficacy, and long-term prognosis (10, 11). This evidence concerns the gene NEFL and myeloid sarcoma.